| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 8,955 | 17,084 | 4,235 | 6,507 |
| Research and development | 55,028 | 39,213 | 42,496 | 40,969 |
| Depreciation, amortization, and impairment | - | - | - | 36,919 |
| Sales and marketing | 2,906 | 3,009 | 2,842 | 3,135 |
| General and administrative | 22,052 | 18,977 | 16,226 | 19,147 |
| Depreciation, amortization, and impairment | 5,247 | 5,470 | 5,331 | - |
| Total operating expenses | 85,233 | 66,669 | 66,895 | 100,170 |
| Loss from operations | -76,278 | -49,585 | -62,660 | -93,663 |
| Interest income | 6,765 | 7,592 | 8,051 | 9,603 |
| Grants and incentives | 2,729 | 3,692 | 4,153 | 3,491 |
| Other | -1,984 | 1,957 | -2,528 | 17,937 |
| Total other income | 7,510 | 13,241 | 9,676 | 31,031 |
| Net loss before income tax | -68,768 | -36,344 | -52,984 | -62,632 |
| Income tax recovery | -11,649 | -1,617 | -7,363 | -11,525 |
| Net loss | -57,119 | -34,727 | -45,621 | -51,107 |
| Foreign currency translation adjustment | -41 | 4,341 | -2,620 | 841 |
| Comprehensive loss | -57,160 | -30,386 | -48,241 | -50,266 |
| Basic (in shares) | 298,875,174 | 298,508,601 | 297,692,663 | 294,851,945 |
| Basic (usd per share) | -0.19 | -0.12 | -0.15 | -0.17 |
| Diluted (in shares) | 298,875,174 | 298,508,601 | 297,692,663 | 294,851,945 |
| Diluted (usd per share) | -0.19 | -0.12 | -0.15 | -0.17 |
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)